Identification of Key MicroRNAs as Predictive Biomarkers of Nilotinib Response in Chronic Myeloid Leukemia: A Sub-Analysis of the ENESTxtnd Clinical Trial

The authors analyzed differentially expressed miRNAs in CD34+ chronic myeloid leukemia cells pre- and post-nilotinib therapy from 58 patients enrolled in the Canadian sub-analysis of the ENESTxtnd Phase IIIb clinical trial.